HY-0102 is under clinical development by Shanghai HyaMab Biotech and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how HY-0102’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

HY-0102 overview

HY-0102 is under development for the treatment of locally advanced and metastatic solid tumors including head and neck cancer, liver cancer, colorectal cancer, lung cancer. The therapeutic candidate is administered through intravenous route.

Shanghai HyaMab Biotech overview

Shanghai HyaMab Biotech (HyaMab Biotech) is a biotech company focusing on treatment of cancers and autoimmune diseases. HyaMab Biotech is headquartered in Shanghai, China.

For a complete picture of HY-0102’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.